)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Alto Neuroscience
Alto Neuroscience (ANRO) investor relations material
Alto Neuroscience TD Cowen 46th Annual Health Care Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.TD Cowen 46th Annual Health Care Conference summary3 Mar, 2026
Strategic focus and pipeline overview
Mission centers on transforming mental health care using precision psychiatry and biomarker-driven approaches.
Pipeline includes late-stage programs for depression, treatment-resistant depression (TRD), bipolar depression, and cognition in schizophrenia.
Two highlighted programs: ALTO-207 (depression/TRD) and ALTO-101 (cognition in schizophrenia).
Additional phase II-B readouts expected this year for ALTO-300 (adjunctive depression) and ALTO-100 (bipolar depression).
Cash runway extends into 2028, supporting multiple upcoming clinical milestones.
ALTO-207: Depression and treatment-resistant depression
ALTO-207 combines pramipexole (dopamine agonist) and ondansetron (antiemetic) to improve efficacy and tolerability.
Phase II-B trial to start in H1 this year, with phase III initiation planned for early next year; pivotal data expected in 2027.
Prior studies (PAXD) showed strong efficacy (Cohen’s d ~0.9 at 12 weeks) and durable response up to 48 weeks in TRD.
Main challenge is tolerability due to nausea/vomiting, addressed by co-formulation and modified release.
IP protection extends into the mid-2040s, covering formulation, titration, and biomarker-defined populations.
ALTO-101: Cognition in schizophrenia
Targets cognitive impairment in schizophrenia using a PDE4 inhibitor with a transdermal formulation for improved tolerability.
Phase I data showed dose-related improvements in EEG biomarkers and cognition.
Ongoing 83-patient crossover trial uses EEG as primary outcome; top-line data expected end of this quarter.
Patient selection based on processing speed impairment enriches for EEG and cognitive deficits.
Trial design aims to de-risk phase II-B by demonstrating circuit engagement and potential cognitive benefit.
ALTO-207: Strategy for broad physician adoption?
ALTO-101: Key de-risking metrics for Phase IIb?
EEG biomarker: Scalability in clinical practice?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Alto Neuroscience
- Phase IIb data for a precision biomarker-driven depression therapy expected in late 2024.ANRO
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - ALTO-100 targets MDD with poor cognition; Phase 2b data expected Oct. 2024, strong market interest.ANROInvestor Day 202421 Jan 2026
- Precision neuroscience trials use digital biomarkers to target and treat subpopulations in depression.ANRO2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026
- Precision biomarker-driven CNS pipeline targets major unmet needs with multiple late-stage trials.ANROCorporate presentation14 Jan 2026
- Phase 2 trials advance with biomarker-driven designs and key readouts expected in 2025.ANROStifel 2024 Healthcare Conference13 Jan 2026
- Q3 net loss widened to $16.8M as R&D spending rose; cash runway extends into 2027 post-IPO.ANROQ3 202412 Jan 2026
- Biomarker-driven trials advance in depression and schizophrenia, with key readouts and strong cash runway.ANROVirtual CNS Forum26 Dec 2025
- Biomarker-driven psychiatry pipeline targets major unmet needs, with four Phase 2 readouts by 2026.ANROLeerink Global Healthcare Conference 202526 Dec 2025
- Precision psychiatry pipeline advances with biomarker-driven trials and key readouts by 2026.ANROTD Cowen 45th Annual Healthcare Conference26 Dec 2025
Next Alto Neuroscience earnings date
Q4 202520 Mar, 2026
Alto Neuroscience
Next Alto Neuroscience earnings date
Q4 202520 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Alto Neuroscience Inc. is a clinical-stage biopharmaceutical company based in the United States, focusing on developing precision medicine for psychiatric conditions. The company leverages AI-derived brain biomarkers to tailor psychiatric drug development to individual patients, aiming to improve treatment effectiveness for mental health issues. Their approach integrates detailed patient-specific data to optimize the drug development process. Alto Neuroscience has a range of products in clinical trials targeting conditions such as major depressive disorder and post-traumatic stress disorder. The company is headquartered in Los Altos, California, and its shares are listed on the NYSE under the ticker ANRO.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage